Finance
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Published by Global Banking & Finance Review®
Posted on February 17, 2026
1 min readLast updated: February 17, 2026
Quick Summary
Bayer's CEO emphasizes the importance of the Roundup settlement in their Supreme Court strategy, aiming to minimize legal risks.
Bayer's Roundup Settlement Key to Supreme Court Case Strategy
Bayer's Legal Strategy and Settlement
BERLIN, Feb 17 (Reuters) - Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anderson said on Tuesday.
Importance of the Settlement
"We are entering into the settlement because it is an important addition to the case before the Supreme Court, thereby minimising the legal risks as comprehensively as possible," he said.
Minimizing Legal Risks
"Both elements are necessary independently of each other and reinforce each other," he added.
(Writing by Friederike HeineEditing by David Goodman)
Key Takeaways
- •Bayer's settlement aims to resolve Roundup claims.
- •The settlement is crucial for the Supreme Court case.
- •Bayer seeks to minimize legal risks comprehensively.
- •CEO Bill Anderson emphasizes dual strategy importance.
- •The settlement and court case strategies are interlinked.
Frequently Asked Questions about Bayer CEO says Roundup settlement is important addition to Supreme Court case
1What is non-Hodgkin lymphoma?
Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, which is part of the body's immune system. It can vary in severity and is often treated with chemotherapy or radiation.
